News

The divestiture includes all of IBAM NA’s cyclotron sites and its research and development facilities. Terms of the transaction were not disclosed. IBA Molecular is jointly owned by

"The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective

The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1

This transaction marks the second CodeEvolver licensing agreement between Codexis and a major pharmaceutical company and advances the technology’s business model of multiple sources of revenue. Under the

Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic and proteomic data that can direct research for improved discovery,

The trials will investigate BGB-283 in patients with B-RAF mutations in a range of tumors where no other effective targeted therapies are currently available in China. In addition,

The partnership builds on a broad existing relationship between the two firms and supports AstraZeneca’s strategic approach in these therapeutic areas using new RNA-targeted treatments as well as

Spritam uses the company’s ZipDose Technology platform which in turn uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid. Earlier,

CL-H1T, which contains fast-dissolving promethazine and sumatriptan, is being developed to treat migraine headache pain and migraine-induced nausea and vomiting (MINV). Charleston Laboratories chief scientific officer Bernard Schachtel